Sean Brusky,  M.B.A.

Sean Brusky joined Prelude Therapeutics in 2024 as Chief Business Officer. He brings over 20 years of biopharma business development, portfolio strategy, and commercialization experience, most recently with Pardes Biosciences where he served as both CCO and CBO. Prior to Pardes, Mr. Brusky spent more than 15 years at Genentech/Roche where he held a variety of market-facing leadership roles in marketing, market access and medical affairs, with a focus on delivering precision oncology innovations to patients. Earlier in his career, he worked in Business & Corporate Development at Vertex Pharmaceuticals and was a management consultant at Bain & Company. Mr. Brusky holds a dual BSc/BA degree in Biochemistry and Molecular Biology from Brown University, and an MBA from Harvard Business School.